文献速递血脂与心血管预防冠心病

脂蛋白(a)与低密度脂蛋白胆固醇介导的心血管风险独立性:参与者水平荟萃分析

Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis.
PubMed 文献 · Circulation · 2024-11-04

结果发现Lp(a)与ASCVD风险呈对数线性关联,且Lp(a)>50 mg/dL时即使LDL-C降至最低四分位(3.1-77.0 mg/dL)风险仍升高(HR 1.38,95%CI 1.06-1.79),Lp(a)与LDL-C风险独立且相加。

要点

  • Lp(a)水平与ASCVD风险呈对数线性关联,不受他汀治疗影响。
  • 他汀治疗后Lp(a)>50 mg/dL者,各LDL-C四分位组ASCVD风险均升高。
  • Lp(a)>50 mg/dL且LDL-C第四四分位者风险最高(HR 1.90)。

核心结论

  • Lp(a)与LDL-C对ASCVD风险的作用独立且相加,降低LDL-C不能完全抵消Lp(a)介导的风险。

主要发现

  • 与Lp(a) 5 mg/dL相比,Lp(a)水平升高与ASCVD风险呈对数线性关联。
  • 他汀治疗者中,Lp(a)>50 mg/dL(≈125 nmol/L)者在达到的LDL-C各四分位及LDL-C绝对变化中风险均增加。
  • 达到LDL-C最低四分位(3.1-77.0 mg/dL)者中,Lp(a)>50 mg/dL者ASCVD风险仍高于Lp(a)≤50 mg/dL者(HR 1.38,95%CI 1.06-1.79)。
  • Lp(a)>50 mg/dL且LDL-C第四四分位者风险最高(HR 1.90,95%CI 1.46-2.48)。

关键数值与推荐

  • Lp(a)阈值50 mg/dL(≈125 nmol/L)用于风险分层。
  • 达到LDL-C最低四分位范围为3.1-77.0 mg/dL。

临床怎么用

  • 对ASCVD高危患者应同时评估Lp(a)和LDL-C水平。
  • Lp(a)>50 mg/dL者即使LDL-C达标,仍应视为残余风险升高。

局限性

  • 研究基于他汀试验人群,可能限制普遍性。
  • 仅评估基线Lp(a)和LDL-C,未涉及治疗干预Lp(a)的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined. METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models. RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1-77.0 mg/dL), those with Lp(a) level >50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06-1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46-2.48]). CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bhatia HS, Wandel S, Willeit P, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2024. PMID: 39492722. doi:10.1161/CIRCULATIONAHA.124.069556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。